Introduction {#S1}
============

Extramedullary disease (EMD) in AML refers to disease found in organs or tissue outside the blood or bone marrow. The most common manifestations of EMD include myeloid sarcomas, leukemia cutis, and meningeal leukemia. Although the exact frequency is unknown, EMD has been estimated to occur in 3 -- 8% of patients with AML, and has been reported to be more common in patients with core-binding factor leukemia, FAB M2/M4/M5, high WBC count and increased age.^[@R1]^ Historically, the presence of EMD has been considered a poor prognostic feature in AML.^[@R2]^ However, the impact of EMD may depend on the site of EMD as well as cytogenetic and molecular features. In adult patients with t(8:21), complete remission (CR) rates (50% vs 92%) and overall survival (OS) (5.4 vs 59.5 months) were markedly worse in patients with EMD treated with standard 7+3 regimens.^[@R3]^ In a retrospective analysis of 434 Japanese patients with AML, myeloid sarcomas were associated with higher relapse rate and lower disease-free survival (DFS).^[@R4]^

Due to its potent antitumor effects, it has been suggested that allogeneic hematopoietic cell transplantation (alloHCT) could overcome the potential poor prognostic impact of EMD in AML. However, data supporting this approach are limited. A retrospective study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) registry of 51 patients with myeloid sarcoma who underwent alloSCT demonstrated an OS of 36% at 5 years confirming that alloSCT is a valid therapeutic option.^[@R5]^ Isolated EMD relapses are common following alloHCT in patients with AML indicating a relative lack of graft vs. leukemia effect in EMD sites.^[@R6]^ Furthermore, reduced intensity conditioning (RIC) regimens, T cell depleted grafts, or non-total body irradiation (TBI) based conditioning regimens have been associated with higher rates of EMD relapse and may reduce the effectiveness of alloHCT in AML with EMD disease.^[@R7]--[@R10]^

Because a prospective study to determine the impact of alloHCT for AML with EMD is not feasible, the Center for International Blood and Marrow Transplant Research (CIMBTR) database offers a comprehensive dataset to identify factors that influence the outcome of alloHCT for AML with EMD. In this study, we compared the outcomes of patients who had EMD of AML at any time prior to transplant to a cohort of AML patients without EMD. We also examined disease-, treatment-, and transplant-related characteristics that affected the outcomes of patients with EMD.

Patients and methods {#S2}
====================

Data source {#S3}
-----------

The CIBMTR, a voluntary working group of more than 500 transplant centers worldwide, contribute data on consecutive allogeneic hematopoietic cell transplants to a statistical center housed both at the Medical College of Wisconsin (Milwaukee, WI) and the National Marrow Donor Program (Minneapolis, MN). Observational studies conducted by CIBMTR are performed with a waiver of informed consent and in compliance with Health Insurance Portability and Accountability Act regulations as determined by the Institutional Review Board and the Privacy Officer of the Medical College of Wisconsin.

Patient selection {#S4}
-----------------

The study population consists of AML patients between 18--70 years of age who underwent bone marrow or peripheral blood alloHCT from either an HLA-identical sibling or unrelated donor between 1995 and 2010. Patients with acute promyelocytic leukemia were excluded.

The site of EMD was determined by the reporting center in one of four categories: CNS, soft tissue, testes, or other. The "other" category was further subdivided into clinically relevant categories such as "skin" and "liver/spleen". Pathologic or radiographic confirmation of EM disease was not required. Cytogenetics were classified according to SWOG/ECOG criteria.^[@R11]^ Conditioning regimens were classified as myeloablative (MA), reduced-intensity (RIC), or non-myeloablative (NMA).^[@R12],\ [@R13]^ CIBMTR classifications of unrelated donor (URD) matching were used to define well-matched, partially matched or mismatched categories.

Study end points and definitions {#S5}
--------------------------------

The primary outcome was overall survival (OS) after alloHCT (defined as the time from transplantation to death). Secondary end points included leukemia-free survival (LFS), relapse rate, and treatment-related (non-relapse) mortality (TRM; defined as any death in the first 28 days after transplantation or any death after day 28 in continuous remission), incidence of grade II--IV acute graft-versus-host disease (GVHD) and the presence of chronic GVHD. Surviving patients were censored at the time of last contact.

Statistical analysis {#S6}
--------------------

Patient-, disease- and treatment-related factors were compared between EMD and non-EMD groups using the Chi-Square tests for categorical and Mann-Whitney test for continuous variables. The probability of LFS and OS were calculated using the Kaplan-Meier estimator, with the variance estimated by Greenwood's formula. Values for other endpoints were calculated using cumulative incidence curves to accommodate competing risks.^[@R14]^

EMD and non-EMD groups were compared using proportional hazards regression models. Risk factors with significant level of p\<0.05 in stepwise model building procedures were included in the outcome models. Potential interactions between the main effect (EMD status) and conditioning intensity, cytogenetic risk and other significant variables were examined.

Results {#S7}
=======

Patient characteristics {#S8}
-----------------------

A total of 9,797 patients were identified from 310 reporting centers and 44 different countries: 814 with EMD prior to alloHCT (EMD group) and 8,983 without EMD pre-transplant (non-EMD group). The median follow-up of survivors was 58 months (range, 3--191 months) for the EMD group and 60 months (range, 3--194 months) for the non-EMD group.

[Table 1](#T1){ref-type="table"} lists patient-, disease-, treatment-, and transplant-related variables for all patients. Patients with EMD tended to be younger (median age of 42 vs. 46 years, p \< 0.001), were more likely to have a monocytic subtype (FAB M4-M5, 46 vs 29%, p \< 0.001), and a higher initial WBC at diagnosis (22 vs 9, p\<0.001). The most common site of EMD was CNS involvement (n=293, 35%). For other sites, 155 (19%) had skin-only and 112 (14%) possessed lymph node-only EMD. An additional 69 (8%) reported multiple sites of EMD.

Transplant conditioning regimens differed between the two groups. In the EMD group, 82% received a MA preparative regimen with 47% receiving a MA conditioning with total body irradiation compared to 75% and 35% respectively in the non-EMD group (p\<0.001 for both comparisons). Disease status prior to conditioning also differed between the non-EMD and EMD groups: primary induction failure (PIF) 15% vs 12%, CR1 49% vs 37%, CR2 or beyond 20% vs 26%, active relapse 17% vs 24%, respectively (p \< 0.001). The duration of first remission was shorter for subjects transplanted in CR2 in the EMD group vs the non-EMD group, 9 vs 11 months (p \< 0.001) with 32% having a CR1 duration of \< 6 months compared to 19% (p \< 0.001) in the non-EMD group.

Univariate analysis of outcomes {#S9}
-------------------------------

Comparisons of outcomes between the EMD and non-EMD groups are listed in [Table 2](#T2){ref-type="table"}. There were no significant differences in LFS or OS, the primary end-points of our study, between patients with and without EMD in univariate analysis ([Figure 1](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}). The 5 year LFS and OS for the EMD group was 33% (95%CI 30--37%) and 36% (95%CI 32--39%) respectively. The relapse rate in the EMD groups was significantly higher at 1 year (33% vs 29%, p = 0.012) and 3 years (39% vs 34%, p = 0.022) post-transplant compared to the non-EMD group. However, this risk was offset by lower rates of TRM post-transplant at 3 years (24% vs 29%, p = 0.009) and 5 years (26% vs 31%, p = 0.009) in the EMD group.

For the 61 patients who proceeded to transplant with active medullary and EMD, univariate analysis showed significantly higher 3-year relapse rate when compared to EMD group (62% vs 39%, p = \<0.001), and significantly worse 3-year LFS (9% vs 37%, p = \<0.001), and OS (10% vs 40%, p = \<0.001). ([Table 2](#T2){ref-type="table"}).

Leukemia was the most common cause of death in the non-EMD group (42%) and EMD group (49%), followed by infection and GVHD ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}). For all patients who relapsed after transplant, there were significant differences in the site of relapse post-transplant ([Supplemental Table 2](#SD2){ref-type="supplementary-material"}). In the EMD group, 26% (14% EM site, 12% peripheral blood (PB)/bone marrow (BM) and EM site) of patients relapsed at extramedullary sites whereas only 9% (5% EM site, 4% PB/BM and EM site) of patients in the non-EMD group relapsed at extramedullary sites. For patients transplanted in ≥ CR2 or at relapse, 23% of the EM group relapsed solely at an EM site post-transplant and 18% relapsed at both medullary and EM sites.

Multivariate analysis of outcomes {#S10}
---------------------------------

Because of the poor outcomes of subjects with both EMD and active marrow disease at the time of transplant, these patients were excluded from the multivariate analysis. Notably, the presence of EMD did not affect either OS (HR 1.00, 95% CI 0.91--1.09; p=0.91) or LFS (0.98, 0.89--1.09; p=0.74). In addition, differences in both TRM (RR 0.92, 95% CI 0.80--1.06, p=0.23) and relapse (RR =1.03, 95% CI, 0.92--1.16; p=0.62) failed to retain their significance in the multivariate model ([Table 4](#T4){ref-type="table"}, [Supplemental Table 4](#SD4){ref-type="supplementary-material"}).

Outcome site of EMD disease or by onset of EMD {#S11}
----------------------------------------------

No significant differences were observed in the rate of relapse, (p=0.66, [Figure 2](#F2){ref-type="fig"}) or OS based on by site of EMD (p=0.28, [Table 3](#T3){ref-type="table"}). We compared the outcomes of the 71 patients who had an isolated granulocytic sarcoma compared to the remaining 743 patients with both EMD and marrow involvement of their leukemia ([Supplemental Table 3](#SD3){ref-type="supplementary-material"}). We also examined the timing of EMD onset, whether EMD was present at the time of diagnosis or at the time of transplantation. Again, in each case, there was no difference in OS between these two groups. ([Table 3](#T3){ref-type="table"})

Pretransplant conditioning {#S12}
--------------------------

Because the GVL effect might be weaker in EM sites^[@R6]^, we also tested for any interaction between the presence of EMD and the intensity of the conditioning regimen on the risk of relapse which might confound our analysis. No interaction was identified between MA and RIC on the risk of relapse (P=0.1591). After MA conditioning, the relative risk of relapse was 1.09 (95% CI, 0.95--1.24; p=0.21) and for RIC was 0.89 (95% CI, 0.70--1.14; p=0.36).

Acute and chronic GVHD {#S13}
----------------------

At day 100, the incidence of grade 2 to 4 acute GVHD was similar between the EMD and non-EMD groups (35% vs 36%, p=0.60, [Table 2](#T2){ref-type="table"}). The incidence of chronic GVHD at 1-, 3-, and 5-years was also similar between the 2 groups.

Discussion {#S14}
==========

This analysis of 814 patients with EM involvement of AML represents the largest and most comprehensive analysis of alloHCT outcomes in this patient population. Historically, EMD has been viewed as a poor prognostic factor, although data supporting this position are limited. For other risk factors in AML such as a monosomal karyotype and FLT3-ITD, the adverse prognostic impact persists despite alloHCT.^[@R15],\ [@R16]^ Unexpectedly, when compared to a non-EMD cohort, we did not identify any impact of EMD itself on either survival, disease relapse, or treatment related mortality. In addition the location, timing of EMD, or intensity of conditioning regimen also did not affect transplant outcomes.

As with any large retrospective registry study, there are important limitations in our analysis. The presence and location of EMD was determined by the reporting center and did not require a confirmatory pathologic or radiographic diagnosis. This may result in underreporting of EMD in locations such as lymph nodes and deep soft tissue sites that can escape detection on routine clinical examination, and over reporting in areas such as the skin, where leukemia cutis may be confused with other dermatologic conditions. At the same time, this mirrors current clinical practice in which no guidelines or standards exist for the evaluation of EMD.

Because of the relative uncommon nature EMD, we are also unable to make meaningful conclusions about specific individual cytogenetic subtypes i.e. t(8:21) or MLL rearrangements, and more uncommon sites of EMD such as testicular involvement. Molecular genetics in AML is a rapidly evolving field and the CIBMTR dataset for AML is limited by lack of uniform molecular characterization of cases. For example, nucleophosmin mutations in cytogenetically normal AML confer a favorable prognosis and have been identified in 15% of isolated myeloid sarcomas though aberrant cytoplasmic localization of the protein by immunohistochemistry.^[@R17]^

Based on our analysis of the CIBMTR, we found that the presence of EMD is not an independent risk factor for relapse, DFS, or OS in patients undergoing alloHCT. Furthermore, the outcome of patients with EMD was not influenced by the location, timing of EMD, or intensity of conditioning regimen.
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###### 

Characteristics of patients between 18 to 70 years of age who underwent allogeneic transplant for AML between 1995 and 2010 reported to the CIBMTR

  Characteristics of patients                                     No-extramedullary disease   Extramedullary   P-value
  --------------------------------------------------------------- --------------------------- ---------------- ---------
  Number of patients                                              8983                        814              
  Number of centers                                               299                         178              
  Age, median (range)                                             46 (18--70)                 42 (18--70)      \<0.001
  Age in decades                                                                                               \<0.001
   18--29                                                         1533 (17)                   199 (24)         
   30--39                                                         1599 (18)                   164 (20)         
   40--49                                                         2311 (26)                   206 (25)         
   50--59                                                         2364 (26)                   186 (23)         
   60--70                                                         1176 (13)                   59 (7)           
  Sex                                                                                                          0.03
   Male                                                           4692 (52)                   458 (56)         
   Female                                                         4291 (48)                   356 (44)         
  Karnofsky score                                                                                              0.01
   \<90%                                                          2877 (32)                   301 (37)         
   \>=90%                                                         5652 (63)                   470 (58)         
   Missing                                                        454 (5)                     43 (5)           
  Sub-disease                                                                                                  \<0.001
   M0-M1                                                          1737 (19)                   124 (15)         
   M2 Myelocytic                                                  2014 (22)                   91 (11)          
   M4-M5                                                          2579 (29)                   374 (46)         
   M6 Erythroblastic                                              311 (3)                     7 (\<1)          
   M7 Megakaryoblastic                                            137 (2)                     12 (1)           
   Granulocytic sarcoma with unknown subtype                      0                           71 (8)           
   AML with t(8;21)(q22;q22)(AML1/ETO)                            39 (\<1)                    8 (\<1)          
   AML with abnormal BM eosinophils (CBFb/MYH11)                  37 (\<1)                    4 (\<1)          
   AML with multi-lineage dysplasia                               530 (6)                     21 (3)           
   AML, other specified                                           250 (3)                     36 (4)           
   AML, subtype unknown                                           1349 (16)                   66 (8)           
  White blood count at diagnosis, ×10\^9/L                                                                     \<0.001
   Median (range)                                                 9 (\<1--1000)               22 (\<1--600)    
   \<= 10                                                         3998 (45)                   253 (31)         
   10 -- 100                                                      2965 (33)                   334 (41)         
   \> 100                                                         707 (8)                     120 (15)         
   Missing                                                        1313 (15)                   107 (13)         
  Cytogenetic abnormalities                                                                                    \<0.001
   Favorable                                                      555 (6)                     72 (9)           
   Intermediate                                                   4129 (46)                   407 (50)         
   Poor                                                           1752 (20)                   140 (17)         
   Missing                                                        2547 (28)                   195 (23)         
  Previous history of MDS                                                                                      \<0.001
   No                                                             7182 (80)                   709 (87)         
   Yes                                                            1709 (19)                   94 (12)          
   Missing                                                        92 (1)                      11 (1)           
  Disease status prior to conditioning                                                                         \<0.001
   Primary induction failure                                      1313 (15)                   97 (12)          
   CR1                                                            4367 (49)                   305 (37)         
   \>=CR2                                                         1773 (20)                   214 (26)         
   Relapse                                                        1530 (17)                   198 (24)         
  Extramedullary disease                                                                                       N/A
   Not present                                                    8983                        0                
   At both diagnosis and transplant                               0                           60 (7)           
   At diagnosis only                                              0                           542 (67)         
   At transplant only                                             0                           159 (20)         
   CNS leukemia present any time prior to conditioning            0                           53 (7)           
  Site of extramedullary disease[a](#TFN1){ref-type="table-fn"}                                                
   Any CNS                                                        0                           283 (35)         
   Skin only                                                      0                           155 (19)         
   Lymph node only                                                0                           112 (14)         
   Other                                                          0                           264 (32)         
   Not applicable                                                 8983                        0                
  Time from extramedullary disease to transplant, months          N/A                         5 (\<1--133)     
  Time from diagnosis to transplant, months                                                                    0.21
   Median (range)                                                 6 (\<1--321)                7 (\<1--200)     0.23
   \<6                                                            4188 (47)                   360 (44)         
   6 -- 12                                                        2451 (27)                   231 (28)         
   \>12                                                           2338 (26)                   221 (27)         
   Missing                                                        6 (\<1)                     2 (\<1)          
  Conditioning regimen combination                                                                             \<0.001
   MA with TBI                                                    3123 (35)                   383 (47)         
   MA without TBI                                                 3562 (40)                   283 (35)         
   RIC/NMA                                                        2298 (26)                   148 (18)         
  Type of donor                                                                                                \<0.001
   HLA-identical sibling                                          3536 (39)                   360 (44)         
   Well-matched unrelated                                         3057 (34)                   243 (30)         
   Partially-matched unrelated                                    1547 (17)                   119 (15)         
   Mismatched unrelated                                           487 (5)                     40 (5)           
   Unrelated unknown                                              356 (4)                     52 (6)           
  Graft type                                                                                                   0.97
   Bone marrow                                                    3229 (36)                   292 (36)         
   Peripheral blood                                               5754 (64)                   522 (64)         
  Year of transplant                                                                                           0.01
   1995--2000                                                     2446 (27)                   259 (32)         
   2001--2005                                                     3213 (36)                   262 (32)         
   2006--2010                                                     3324 (37)                   293 (36)         
  Median follow-up of survivors (range), months                   60 (3--194)                 58 (3--191)      
  **[Patients transplanted in CR2 only]{.ul}**                    1649                        200              
  Duration of CR1, months                                                                                      \<0.001
   Median (range)                                                 11 (\<1--187)               9 (\<1--110)     \<0.001
   \<6                                                            308 (19)                    63 (32)          
   6 -- 12                                                        475 (29)                    59 (30)          
   \>12                                                           631 (38)                    53 (27)          
   Missing                                                        235 (14)                    25 (13)          

Other sites of extramedullary disease include:

liver/spleen only, n=45; multiple sites, n=69; other specified, n=150

example of other specified: pelvic soft tissue mass; salivary gland chloroma; mass in right lung base; gum pyperplacy ecxema (paws); breast infiltrate; left mandible; gastric chloroma; bone (knee); thorencentesis fluid; polychondritis etc.

###### 

Univariate analysis of outcomes

                                No-EMD (N = 8983)   EMD (N = 814)   EMD and MD at HCT                       
  ----------------------------- ------------------- --------------- ------------------- -------------- ---- -----------------------------------
  Acute GVHD, grade II--IV      8938                                811                                61   
   100-day                                          36 (35--37)%                        35 (32--38)%        38 (26--51)%
  Chronic GVHD                  8712                                793                                59   
   1-year                                           41 (40--42)%                        42 (38--45)%        25 (14--38)%
   3-year                                           45 (44--46)%                        45 (42--49)%        28 (16--41)%
   5-year                                           46 (44--47)%                        46 (42--49)%        28 (16--41)%
  Relapse                       8877                                804                                60   
   1-year                                           29 (28--29)%                        33 (30--37)%        58 (45--70)%
   3-year                                           34 (33--35)%                        39 (36--43)%        62 (48--73)%
   5-year                                           36 (35--37)%                        41 (37--44)%        62 (48--73)%
  Treatment related mortality   8877                                804                                60   
   1-year                                           24 (23--25)%                        20 (18--23)%        25 (15--37)%
   3-year                                           29 (28--30)%                        24 (21--27)%        29 (18--41)%
   5-year                                           31 (30--32)%                        26 (23--29)%        35 (22--48)%
  Leukemia free survival        8877                                804                                60   
   1-year                                           48 (47--49)%                        46 (43--50)%        17 (8--27)%
   3-year                                           37 (36--38)%                        37 (33--40)%        9 (3--18)%
   5-year                                           33 (32--34)%                        33 (30--37)%        NE[†](#TFN4){ref-type="table-fn"}
  Overall survival              8983                                814                                61   
   1-year                                           54 (53--55)%                        53 (50--57)%        21 (12--32)%
   3-year                                           40 (39--41)%                        40 (37--44)%        10 (4--20)%
   5-year                                           35 (34--37)%                        36 (32--39)%        5 (1--13)%

No case at risk at this time point

Gray's test: p=0.92 for aGVHD, p=0.21 for cGVHD, p\<0.001 for relapse, p=0.031 for TRM.

Log-rank test: p\<0.001 for DFS, p\<0.001 for OS

###### 

Univariate analysis based on EMD site and time of EMD onset

  [EMD site]{.ul}                                                                                                              
  ------------------ ----- -------------- ----- -------------- ----- -------------- ----- -------------- ------ -------------- ------
  Overall survival   283                  155                  112                  264                  8983                  
   1-year                  55 (49--60)%         44 (36--52)%         60 (50--69)%         54 (48--60)%          54 (53--55)%   0.11
   3-year                  42 (36--48)%         35 (27--42)%         43 (33--52)%         41 (35--47)%          40 (39--41)%   0.62
   5-year                  39 (33--45)%         28 (21--36)%         34 (25--44)%         37 (31--44)%          35 (34--37)%   0.28

  [Time of EMD onset]{.ul}                                                                   
  -------------------------- ----- -------------- ----- -------------- ------ -------------- ------
  Overall survival           602                  159                  8983                  
   1-year                          55 (51--59)%         45 (37--53)%          54 (53--55)%   0.07
   3-year                          42 (38--46)%         34 (26--41)%          40 (39--41)%   0.15
   5-year                          37 (33--41)%         30 (22--37)%          35 (34--37)%   0.27

###### 

Multivariate analysis of outcome

                                           Univariate          Multivariate[‡](#TFN7){ref-type="table-fn"}                       
  --------------------------------- ------ ------------------- --------------------------------------------- ------------------- ------
  **Overall Survival**                                                                                                           
   no-EMD                           8983   1.00                0.73                                          1.00                0.91
   EMD                              814    1.02 (9.03--1.11)                                                 1.00 (0.91--1.09)   
  **Leukemia Free Survival**                                                                                                     
   no-EMD                           8877   1.00                0.58                                          1.00                0.74
   EMD                              804    1.03 (0.94--1.12)                                                 0.98 (0.89--1.09)   
  **Treatment Related Mortality**                                                                                                
   no-EMD                           8877   1.00                0.05                                          1.00                0.23
   EMD                              804    0.87 (0.76--1.00)                                                 0.92 (0.80--1.06)   
  **Relapse**                                                                                                                    
   no-EMD                           8877   1.00                0.01                                          1.00                0.62
   EMD                              804    1.16 (1.03--1.30)                                                 1.03 (0.92--1.16)   

MVA model adjusted for: WBC at diagnosis, previous history of MDS, cytogenetic risk group, disease status prior to HSCT, duration of CR1, site of relapse for patients transplanted in \>=CR2, time from diagnosis to HSCT, consolidation treatment, age group, conditioning regimen, type of donor, graft type, CMV serostatus, year of HSCT, GVHD prophylaxis.

DLI was excluded from model.
